Login
← Go Back
Bafna Pharmaceuticals
BAFNAPH · Pharma > Pharmaceuticals & Drugs · Chairman: Shanmugam Hemalatha Listing date: Nov. 13, 2012
Stock Price vs Company Growth
1d
4.7%
1w
5.2%
1m
29.1%
3m
21.2%
6m
36.0%
1y
49.6%
5y
1.7%
10y
13.1%
all
7.6%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 122 4.7%
111
205
Company Overview
Sales
142 Cr
Growth: 1.7%
Profit after Tax
8.78 Cr
Growth: 6.2%
Micro Cap
288 Cr
P/E: 32.9x
Industry P/E: 30.3x
Fundamentals
Sales (Cr) ₹ 142
Growth 1.7%
EBITDA 10.9%
P/S 2.0x
Dividend 0.0%
P/E 32.9x
Book Value ₹ 38.6
PEG Ratio 17.3x
ROE 10.1%
P/B 2.9x
Shareholding Pattern
Institutions
Promoters
Srjr Lifesciences Llp
90.0 %
Paras Bafna
0.21 %
Navin Bafna M
0.17 %
Amribai Bafna
0.01 %
Others
Monarch Networth Finserve Private Limited
1.4 %
Increase    Decrease    No change
Company Profile Detailed
Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy.
Investors (54)
mahaveer...
paras.ba...
monarch....